UNASSIGNED: A systematic review protocol was registered with PROSPERO and reported in accordance with the Preferred Reporting for Items for Systematic Reviews and Meta-Analyses. Comprehensive electronic search strategies were devised, and studies were screened based on predefined inclusion and exclusion criteria.
UNASSIGNED: Ten articles met the eligibility criteria, encompassing a total of 135 patients diagnosed with DSO who received bisphosphonate treatment. All included studies consistently reported a reduction in pain levels and swelling, along with a decrease in the cumulative use of analgesics. The majority of patients reported long-lasting symptom improvement with bisphosphonate therapy. Notably, four studies documented improvements in maximal mouth opening, with one study reporting a mean increase of 9.6mm. Furthermore, six studies observed improvements in panoramic radiographs and cone beam computed tomography scans, with one publication describing two patients exhibiting near-normal bone architecture. Importantly, all studies reported the absence of long-term complications.
UNASSIGNED: Bisphosphonate therapy emerges as a promising treatment modality for DSO, exhibiting efficacy in symptom alleviation and radiological enhancement while conferring lasting benefits. Nevertheless, further prospective studies are warranted to refine treatment protocols and substantiate these findings.
■系统评价方案在PROSPERO注册,并根据系统评价和荟萃分析项目的首选报告进行报告。设计了全面的电子搜索策略,根据预定义的纳入和排除标准对研究进行筛选.
■十篇文章符合资格标准,共135例接受双膦酸盐治疗的DSO患者。所有纳入的研究一致报告疼痛程度和肿胀减轻,随着止痛药的累积使用量的减少。大多数患者报告双膦酸盐治疗长期症状改善。值得注意的是,四项研究记录了最大张口的改善,一项研究报告平均增加9.6毫米。此外,六项研究观察到全景射线照片和锥形束计算机断层扫描的改善,一份出版物描述了两名表现出接近正常骨骼结构的患者。重要的是,所有研究均报告无长期并发症.
■双膦酸盐治疗成为DSO的一种有希望的治疗方式,在症状缓解和放射学增强方面表现出功效,同时赋予持久的益处。然而,需要进一步的前瞻性研究来完善治疗方案并证实这些发现.